Clinical Trial Search

Primary: Change in Urine cAMP — 3048 fm/uL

Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale

Primary: Peak Oxygen Consumption (VO2 Peak) — 16.6; 16.1 milliliters per kilogram per minute

Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L

Primary: Mean Stimulated C-peptide Area Under the Curve — 0.28; 0.27; 0.25 pmol/ml — p=0.47

Primary: Self-reported Severe Hypoglycemia — 99; 99; 19; 13 Participants — p=0.27

Primary: Serologic, Genetic and Inflammatory Markers Consistent With Inflammatory Bowel Disease — 11 participants testing positive

Primary: Triglycerides Post-prandial — 95; 71; 134 mmol/L

Primary: HbA1c (%) — 7.92; 7.48; 7.45; 7.58 Percent of Hemoglobin (%)

Primary: Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo — 0.088; 0.102 Proportion with diabetes/year

Primary: Side Effects of Salsalate — 3 participants

Primary: Difference in Insulin Resistance (HOMA) Between Treatments After 12 Weeks of Product Intake — 2.82; 2.21; 2.75 HOMA index

Primary: HbA1c Change — -0.1; -0.1 HbA1c percent

Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change

Primary: Occurrence of Alloanti-D Immunization in Asian-type DEL Recipients Transfused With RhD+ RBCs — 42; 12 Participants — p=< 0.001